ApconiX at the ELRIG Drug Discovery Conference 2016!

We had an exciting two days exhibiting at the European Laboratory Research & Innovation Group (ELRIG) Drug Discovery conference 2016 in Liverpool. Many new and old colleagues were interested to hear what services ApconiX offer and the successes we have had over the past year. It was a great team success creating the stall and literature which had a lot of interest in the innovation zone of ELRIG.

 

Besides the company stand we had fun attending workshops and talks such as, drug safety in drug development, safety/toxicology models and immuno-oncology. In particular, Chas Bountra’s talk on the integration of academia, biotech and pharma named: “How can we build a new drug discovery ecosystem, which will complement Boston?” was very insightful in highlighting the crucial aspect of pooling resources in order for more efficient future drug discovery. Throughout the talk it was evident how academia and the pharmaceutical industry differ. Academia is based on the specialisation of research for many years which is complemented by easy access to public databases. Whereas in the pharmaceutical industry quick turn over is required meaning that research projects last only 6 months with a much restricted public data access. This plenary keynote was of particular interest to us as at ApconiX as we take pride in our ability to help innovative biotech companies and universities realize their ambitions in drug discovery and development. Therefore, it is reassuring for us to know that we are creating a symbiotic relationship with academia and biotech companies in order to build a successful drug discovery ecosystem.

By |2018-06-06T14:52:45+00:00October 24th, 2016|Events|Comments Off on ApconiX at the ELRIG Drug Discovery Conference 2016!

About the Author:

Professor Ruth A Roberts, PhD, ATS, FBTS, ERT, FRSB, FRCPath Director and Cofounder, ApconiX, UK and Chair and Director of Drug Discovery, University of Birmingham, UK Ruth is chair of drug discovery at Birmingham University, UK and Cofounder of ApconiX, an integrated toxicology and ion channel company that brings together a team of world-renowned nonclinical safety experts with over 400 years of drug discovery and development experience. Previously, Ruth was Global Head of Regulatory Safety at AstraZeneca and Director of Toxicology for Aventis. Ruth is an established science professional bringing rigorous expert thinking to toxicology, drug discovery and drug development. With >140 publications in peer reviewed journals, she is focused on reducing attrition attributable to safety and toxicity. A former president of the British Toxicology Society, former president of EUROTOX, former secretary to SOT and president elect of the Academy of Toxicological Sciences, Ruth was the recipient of the SOT Achievement award in 2002, the EUROTOX Bo Holmstedt Award in 2009 and the SOT Founders award in 2018 for outstanding leadership in toxicology.